ProAp: Colonic Propionate, Appetite, and Weight Loss

• Sponsor: Imperial College London (Other)
• Overall Status: Completed
• CT.gov ID: NCT03322514
• Collaborator: University of Glasgow (Other)
• Enrollment: 12
• Location: 1
• Arms: 2
• Actual Duration (Months): 7.5
• Patients Per Site Per Month: 1.6

Study Details

Study Description

Brief Summary

The current protocol aims to investigate the impact of the propionate ester in conjugation with restricted diet on appetite and weight loss.

Condition or Disease	Intervention/Treatment	Phase
Healthy Obesity, Metabolically; Appetite Regulation	Dietary Supplement: Inulin-Propionate Esters; Dietary Supplement: Inulin	N/A

Detailed Description

DIET AND OBESITY:

Obesity has reached epidemic proportions worldwide. In the United Kingdom, 58% of adult women and 65% of adult men are either overweight or obese (Health and Social Care Information Centre 2014), with the expectation that rates will increase (Ng et al. 2014). Obesity, mainly caused by a chronic positive energy balance, is a known risk factor that contributes to the development of type 2 diabetes and cardiovascular diseases, and the subsequent morbidities and mortalities (Kopelman 2007). A positive energy balance is inevitable with the composition of current western diet that contain refined (fibre-depleted) carbohydrates that are consumed quickly, and have minimal effects on long-term satiety (Cleave 1974; Heaton 1973).

NONDIGESTIBLE CARBOHYDRATES:

The quality and quantity of diet has changed dramatically over the last fifty years. Of which, carbohydrates have the most significant changes; from unprocessed fruits and vegetables based carbohydrates to more processed cereal based ones (Cordain et al. 2005). Epidemiological studies have shown that, as a result, ancestral diets had greater amounts of Non-Digestible Carbohydrates (NDC) than modern diets (>100g/day compared to <15g/day) with the inclusion of more indigestible intact cell wall plant material, such as tubers, grasses and sedges (Eaton 2006). A strong association has been established between increased weight gain with decreased NDC intake (Liu et al. 2003). Furthermore, increasing intake of NDC have shown to induce satiety and improve body composition in animals (So et al. 2007) and humans (Bouché et al. 2002).

LOW CALORIC HIGH NDC DIET IN LOSING WEIGHT Applying energy-restricted diets is one of the first steps to treat obesity. However, weight regain in weight maintenance period could happen due to resting energy expenditure reduction and lean mass loss. The inclusion of specific foods to the nutritional intervention is being investigated in order to produce persistent weight losses (Abete et al. 2008). It was suggested earlier that the addition of high fibre NDC foods to a hypocaloric diet would help reducing the incidence of metabolic syndrome and increasing the dietary compliance (Hermana et al, 2011). The high fibre content in combination with a low glycemic index diet, can both result in higher satiety effects with an increased mitochondrial oxidation, all favour weight loss.

PROPIONATE AND THE FFAR2 RECEPTOR:

Production of short chain fatty acids (SCFA) is the main by-product of NDC colonic fermentation (Pawlak et al. 2004). Of them, colonic propionate was found to play a critical role directly in the colon and systematically after its absorption into the circulation (Wong et al. 2006). Free Fatty Acid Receptor 2 (previously known as orphan G-coupled Protein Receptor 43) has been discovered to has high affinity to propionate (Brown et al. 2003). It is expressed on the distal ileum and colon L-enteroendocrine cells (Karaki et al. 2008), adipocytes and certain monocytes lineage (Hong et al. 2005).

THE ROLE OF PROPIONATE IN GUT HORMONE RELEASE AND APPETITE REGULATION:

The L-enteroendocrine colonic cells are responsible of secreting anorexic gut hormones (PYY and GLP-1) physiologically in response to food. These hormones are capable of inducing satiety through signalling the brain appetite centre (Murphy & Bloom 2006). Propionate-induced FFAR2 activation have found to cause the release of these hormones in vitro. Moreover, NDC ingestion was found to stimulate the release of these hormones in animals, resulting in decreasing food ingestion (Delzenne et al. 2005). Propionate was shown to replicate the same effects in further studies, suggesting the owning of the beneficial effects of NDC on appetite and gut hormones to propionate production.

SHORT CHAIN FATTY ACID ESTER:

Administering NDCs that promote the production of propionate is an attractive way to increase the level of propionate over an extended period of time. However, due to variability of the gut microbita activity, administering high proportions (≥ 35g/d) of dietary fibres in human diets to increase colonic propionate does not reliably or predictably provide the same SCFA levels in colon or systemically (Cummings 1981). Oral propionate supplementation is another method, but unfortunately its short plasma half-life, poor palatability, and the fact that its main absorption happens in the small intestine limit its use as a food supplement (Frost et al. 2003).

A novel system has been developed by Dr Douglas Morrison, (Scottish Universities Environmental Research Centre (SUERC)). This molecule of inulin (β(2-1) linked polymer of fructose) carrier with an ester linked to propionate (propionate ester) was demonstrated to reliably and reproducibly increase colonic propionate while prevent the side effects of NDC (Chambers et al. 2015). Thus, propionate is only released when the carrier molecule inulin is fermented by colon microflora, which was estimated to be 180 minutes post-ingestion. (Chambers et al. 2014). Chambers et al. (2015) were able to show that 10g of Inulin-Propionate Esters (IPE) has the ability to deliver 2.4g of propionate to the colon, that is an increment of 2.5-fold of propionate production in the colon, a level that is achieved only with 60g/d via traditional dietary fibre supplementation. The same group has also demonstrated that while the acute administration of this supplement caused increments in Plasma GLP-1 and PYY and reduced food ingestion, the long term (24 weeks) supplementation of propionate ester significantly reduced body weight gain and the development of abdominal adipose tissue (Chambers et al. 2014). Interestingly, none of the long term participants reported any side effects from the intake of propionate esters. Increasing colonic propionate is, therefore, one of the attractive strategies to manage weight and diabetes risk factors.

The current protocol aims to investigate the impact of the propionate ester in conjugation with restricted diet on appetite and weight loss.

Study Design

• Study Type: Interventional
• Actual Enrollment: 12 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Intervention Model Description: double blind, randomised, controlled, paralleled studydouble blind, randomised, controlled, paralleled study
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Prevention
• Official Title: Effect of Increased Colonic Propionate on Weight Loss During a Hypo-caloric Diet.
• Actual Study Start Date: Mar 29, 2017
• Actual Primary Completion Date: Nov 11, 2017
• Actual Study Completion Date: Nov 11, 2017

Arms and Interventions

Arm	Intervention/Treatment
Experimental: experimental group 10 g of Inulin-Propionate Esters will be administered per day	Dietary Supplement: Inulin-Propionate Esters; Inulin (β(2-1) linked polymer of fructose) carrier with an ester linked to propionate (propionate ester). Thus, propionate is only released when the carrier molecule inulin is fermented by colon microflora.
Active Comparator: Inulin 10 g of Inulin will be administered per day	Dietary Supplement: Inulin; Inulin

Outcome Measures

Primary Outcome Measures

1. Change in Weight Loss Compared to Baseline [Baseline and 12 weeks]

   The weight assessed by a body scale

Secondary Outcome Measures

1. Glucose Blood Level Baseline to 12 Weeks [Baseline, 12 weeks]

2. Insulin Level in Serum [Baseline, 12 weeks]

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 65 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Inclusion Criteria:

• overweight or obese ((BMI) of 25-35 kg/m2)

• healthy

• aged between 18 and 65 years

Exclusion Criteria:

• Weight change of ≥ 3kg in the preceding 2 months

• Undergone any weight loss surgery or gastric procedures to promote weight loss

• Current smokers

• Substance abuse

• Excess alcohol intake

• Pregnancy

• Diabetes

• Cardiovascular disease

• Cancer

• Gastrointestinal disease e.g. inflammatory bowel disease or irritable bowel syndrome

• Kidney disease

• Liver disease

• Pancreatitis

• Use of medications likely to interfere with energy metabolism, appetite regulation and hormonal balance, including: anti-inflammatory drugs or steroids, antibiotics, androgens, phenytoin, erythromycin or thyroid hormones.

Any participants with the above conditions would already have an altered pattern of hormones and inflammatory molecules because of their disease process and would therefore give us confounding or misleading results.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	NIHR/Wellcome Trust Imperial Clinicial Research Facility	London		United Kingdom	W12 0NN

Sponsors and Collaborators

• Imperial College London
• University of Glasgow

Investigators

• Principal Investigator: Gary Frost, Dietitian; PhD in Nutrition; Professor of nutrition and dietetics

Study Documents (Full-Text)

• Study Protocol and Statistical Analysis Plan - Jan 24, 2017

More Information

Publications

None provided.

• Responsible Party: Imperial College London
• ClinicalTrials.gov Identifier: NCT03322514
• Other Study ID Numbers: 16HH3560; 210536
• First Posted: Oct 26, 2017
• Last Update Posted: Nov 20, 2019
• Last Verified: Nov 1, 2019

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Keywords provided by Imperial College London: gut hormones; obesity; appetite; propionate; fermentation
• Additional relevant MeSH terms: Obesity, Metabolically Benign; Weight Loss

Study Results

Participant Flow

Arm/Group Title	Experimental Group	Inulin
Arm/Group Description	10 g of Inulin-Propionate Esters will be administered per day Inulin-Propionate Esters: Inulin (β(2-1) linked polymer of fructose) carrier with an ester linked to propionate (propionate ester). Thus, propionate is only released when the carrier molecule inulin is fermented by colon microflora.	10 g of Inulin will be administered per day Inulin: Inulin
Period Title: Overall Study
STARTED	6	6
COMPLETED	5	5
NOT COMPLETED	1	1

Baseline Characteristics

Arm/Group Title	Experimental Group	Inulin	Total
Arm/Group Description	10 g of Inulin-Propionate Esters will be administered per day Inulin-Propionate Esters: Inulin (β(2-1) linked polymer of fructose) carrier with an ester linked to propionate (propionate ester). Thus, propionate is only released when the carrier molecule inulin is fermented by colon microflora.	10 g of Inulin will be administered per day Inulin: Inulin	Total of all reporting groups
Overall Participants	6	6	12
Age (Count of Participants)
<=18 years	0 0%	0 0%	0 0%
Between 18 and 65 years	6 100%	6 100%	12 100%
>=65 years	0 0%	0 0%	0 0%
Age (years) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [years]	30.6 (5.9)	35.2 (12.1)	33.4 (8.9)
Sex: Female, Male (Count of Participants)
Female	4 66.7%	5 83.3%	9 75%
Male	2 33.3%	1 16.7%	3 25%
Race and Ethnicity Not Collected (Count of Participants)
Count of Participants [Participants]	0 0%
Region of Enrollment (participants) [Number]
United Kingdom	6 100%	6 100%	12 100%

Outcome Measures

1. Primary Outcome

Title	Change in Weight Loss Compared to Baseline
Description	The weight assessed by a body scale
Time Frame	Baseline and 12 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Experimental Group	Inulin
Arm/Group Description	10 g of Inulin-Propionate Esters administered per day	10 g of Inulin administered per day
Measure Participants	5	5
Mean (Standard Error) [kg]	-2.6 (0.9)	-3 (1.04)

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Experimental Group, Inulin
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.8
	Comments
	Method	t-test, 2 sided
	Comments

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	Experimental Group
	Comments	Baseline to 12 weeks
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.04
	Comments
	Method	t-test, 2 sided
	Comments

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	Inulin
	Comments	Baseline to 12 weeks
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.1
	Comments
	Method	t-test, 2 sided
	Comments

2. Secondary Outcome

Title	Glucose Blood Level Baseline to 12 Weeks
Time Frame	Baseline, 12 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Experimental Group	Inulin
Arm/Group Description	10 g of Inulin-Propionate Esters administered per day	10 g of Inulin administered per day
Measure Participants	5	5
Baseline	4.9 (0.1)	4.4 (0.1)
12 weeks	5.1 (0.1)	4.8 (0.1)

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Experimental Group, Inulin
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.8
	Comments
	Method	ANOVA
	Comments

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	Experimental Group
	Comments	Baseline to 12 weeks
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.3
	Comments
	Method	t-test, 2 sided
	Comments

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	Inulin
	Comments	Baseline to 12 weeks
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.3
	Comments
	Method	t-test, 2 sided
	Comments

3. Secondary Outcome

Title	Insulin Level in Serum
Time Frame	Baseline, 12 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Experimental Group	Inulin
Arm/Group Description	10 g of Inulin-Propionate Esters administered per day	10 g of Inulin administered per day
Measure Participants	5	5
Baseline	50.4 (10.8)	48.9 (18.3)
12 weeks	41.0 (6.7)	46.0 (21.1)

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Experimental Group, Inulin
	Comments
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.9
	Comments
	Method	ANOVA
	Comments

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	Experimental Group
	Comments	Baseline to 12 weeks
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.4
	Comments
	Method	t-test, 2 sided
	Comments

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	Inulin
	Comments	baseline to 12 weeks
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.7
	Comments
	Method	t-test, 2 sided
	Comments

Adverse Events

Time Frame	12 weeks
Arm/Group Title	Experimental Group		Inulin
Arm/Group Description	10 g of Inulin-Propionate Esters will be administered per day Inulin-Propionate Esters: Inulin (β(2-1) linked polymer of fructose) carrier with an ester linked to propionate (propionate ester). Thus, propionate is only released when the carrier molecule inulin is fermented by colon microflora.		10 g of Inulin will be administered per day Inulin: Inulin
All Cause Mortality
	Experimental Group		Inulin
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	0/6 (0%)		0/6 (0%)
Serious Adverse Events
	Experimental Group		Inulin
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	0/6 (0%)		0/6 (0%)
Other (Not Including Serious) Adverse Events
	Experimental Group		Inulin
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	0/6 (0%)		0/6 (0%)

Limitations/Caveats

[Not Specified]

More Information

Certain Agreements

All Principal Investigators ARE employed by the organization sponsoring the study.

There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.